(5-vinyl-1,3-phenylene)bis(oxy)bis(tert-butyldimethylsilane)

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (5-vinyl-1,3-phenylene)bis(oxy)bis(tert-butyldimethylsilane)
• 英文别名: 1,3-di-(tert-butyldimethylsilyloxy)-5-vinylbenzene；3,5-bis(tert-butyldimethylsilyloxy)styrene；3,5-dii(tert-butyldimethylsilyloxy)-styrene；3,5-Bis[dimethyl(tert-butyl)silyloxy]styrene；tert-butyl-[3-[tert-butyl(dimethyl)silyl]oxy-5-ethenylphenoxy]-dimethylsilane
• 化学式: C₂₀H₃₆O₂Si₂
• 分子量: 364.676
• InChiKey: RHMQZMRZZVIEGL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.1
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (5-vinyl-1,3-phenylene)bis(oxy)bis(tert-butyldimethylsilane) 在 甲醇 、 四丁基氟化铵 、 palladium diacetate 、 potassium carbonate 、 三乙胺 、 三(邻甲基苯基)磷 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 丹叶大黄素-3'-O-葡萄糖苷
  参考文献：
  名称：

  Piceatannol-3'-O-β-d-吡喃葡萄糖苷及其4'-甲氧基同系物的可扩展全合成：早期糖基化策略

  摘要：

  实现了 piceatannol-3'-O-β-d-吡喃葡萄糖苷及其 4'-甲氧基同类物的可扩展合成。该路线具有早期实施的 Fischer 样糖基化反应、酚糖苷在强酸性条件下的区域选择性碘化、获得苯乙烯衍生物的高度伸缩路线以及关键的 Mizoroki-Heck 反应，以高总产率提供所需的偶联产物.

  DOI：

  10.1055/a-1639-0648
• 作为产物：
  描述：

  3,5-二羟基苯甲醛 在 咪唑 、 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 34.0h， 生成 (5-vinyl-1,3-phenylene)bis(oxy)bis(tert-butyldimethylsilane)
  参考文献：
  名称：

  [EN] XYLOSIDE DERIVATIVES OF RESVERATROL FOR USE THEREOF IN COSMETICS
  [FR] DÉRIVÉS XYLOSIDES DE RESVÉRATROL POUR LEUR UTILISATION EN COSMÉTIQUE

  摘要：

  本发明涉及使用以下化合物的使用：其中R1、R2和R3独立表示：-公式(II)的基团，或-氢原子H，理解至少一个基团R1、R2、R3表示为公式(II)的基团；以及其盐、溶剂合物和/或异构体，用于预防和/或美容治疗皮肤衰老迹象。

  公开号：

  WO2019122140A1

文献信息

• MOLECULARLY IMPRINTED POLYMERS
  申请人：Hearn Milton T. W.

  公开号：US20120052757A1

  公开（公告）日：2012-03-01

  The present invention provides methods of designing molecularly imprinted polymers (MIPs) which have applications in extracting bioactive compounds from a range of bioprocessing feedstocks and wastes. The present invention is further directed to MIPs designed by the methods of the present invention.

  本发明提供了设计分子印迹聚合物（MIPs）的方法，这些方法在从各种生物加工原料和废弃物中提取生物活性化合物方面具有应用。本发明进一步针对由本发明方法设计的MIPs。
• Acid-Catalyzed Ring-Opening Cyclization of Spirocyclopropanes for the Construction of a 2-Arylbenzofuran Skeleton: Total Synthesis of Cuspidan B
  作者：Hisanori Nambu、Takayuki Yakura、Naoki Ono

  DOI：10.1055/s-0035-1561590

  日期：——

  Abstract Acid-catalyzed ring-opening cyclization of cyclohexane-1,3-dione-2-spirocyclopropanes under metal-free conditions proceeded smoothly at room temperature to provide 2-aryl-3,5,6,7-tetrahydro-1-benzofuran-4(2H)-ones in excellent yields without the formation of 3-substituted isomers. The obtained product was converted into a 2-arylbenzofuran derivative via a synthetically useful 2-aryl-2,3-dihydrobenzofuran

  摘要 在无金属条件下，环己烷-1,3-二酮-2-螺环丙烷的酸催化开环环化反应在室温下顺利进行，得到2-芳基-3,5,6,7-四氢-1-苯并呋喃-4 （2 H）-一的产率极高，而不会形成3-取代的异构体。所得产物通过合成上有用的2-芳基-2，3-二氢苯并呋喃中间体转化为2-芳基苯并呋喃衍生物。此外，通过使用本方法实现了cuspidan B的第一全合成。 在无金属条件下，环己烷-1,3-二酮-2-螺环丙烷的酸催化开环环化反应在室温下顺利进行，得到2-芳基-3,5,6,7-四氢-1-苯并呋喃-4 （2 H）-一的产率极高，而不会形成3-取代的异构体。所得产物通过合成上有用的2-芳基-2，3-二氢苯并呋喃中间体转化为2-芳基苯并呋喃衍生物。此外，通过使用本方法实现了cuspidan B的第一全合成。
• Anti-diabetic activity of fused PPARγ-SIRT1 ligands with limited body-weight gain by mimicking calorie restriction and decreasing SGK1 expression
  作者：Celine Pirat、Catherine Dacquet、Veronique Leclerc、Nathalie Hennuyer、Monique Beucher-Gaudin、Ghislaine Zanirato、Anne Géant、Bart Staels、Alain Ktorza、Amaury Farce、Daniel-Henri Caignard、Pascal Berthelot、Nicolas Lebegue

  DOI：10.1016/j.ejmech.2017.06.006

  日期：2017.9

  A series of benzothiazol-2-one containing alpha-ethoxyphenylpropionic acid derivatives incorporating resveratrol or butein scaffolds were designed as fused full PPAR gamma agonist ligands and SIRT1-activating compounds for the treatment of type 2 diabetes (T2D) and its complications. Compound 14d displayed the best in vitro pharmacological profile with full PPAR gamma agonist activity (Emax = 98%, EC50 = 200 nM), SIRTI enzymatic activation (+128%) and SGK1 expression inhibition (- 57%) which is known to limit side effects as fluid retention and body-weight gain. Compound 14d showed high efficacy in an ob/ob mice model with significant decreases in serum triglyceride, glucose and insulin levels but mostly with limited body-weight gain by mimicking calorie restriction (CR) and inhibiting SGKI expression. (C) 2017 Elsevier Masson SAS. All rights reserved.
• Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer
  作者：Bin Sun、Juma Hoshino、Katie Jermihov、Laura Marler、John M. Pezzuto、Andrew D. Mesecar、Mark Cushman

  DOI：10.1016/j.bmc.2010.05.042

  日期：2010.7

  A series of new resveratrol analogues were designed and synthesized and their inhibitory activities against aromatase were evaluated. The crystal structure of human aromatase (PDB 3eqm) was used to rationalize the mechanism of action of the aromatase inhibitor 32 (IC50 0.59 mu M) through docking, molecular mechanics energy minimization, and computer graphics molecular modeling, and the information was utilized to design several very potent inhibitors, including compounds 82 (IC50 70 nM) and 84 (IC50 36 nM). The aromatase inhibitory activities of these compounds are much more potent than that for the lead compound resveratrol, which has an IC50 of 80 mu M. In addition to aromatase inhibitory activity, compounds 32 and 44 also displayed potent QR2 inhibitory activity (IC50 1.7 mu M and 0.27 mu M, respectively) and the high-resolution X-ray structures of QR2 in complex with these two compounds provide insight into their mechanism of QR2 inhibition. The aromatase and quinone reductase inhibitors resulting from these studies have potential value in the treatment and prevention of cancer. (C) 2010 Elsevier Ltd. All rights reserved.
• Selective Synthesis and Biological Evaluation of Sulfate-Conjugated Resveratrol Metabolites
  作者：Juma Hoshino、Eun-Jung Park、Tamara P. Kondratyuk、Laura Marler、John M. Pezzuto、Richard B. van Breemen、Shunyan Mo、Yongchao Li、Mark Cushman

  DOI：10.1021/jm100274c

  日期：2010.7.8

  Five resveratrol sulfate metabolites were synthesized and assessed for activities known to be mediated by resveratrol: inhibition of tumor necrosis factor (TNF)alpha induced NF kappa B activity, cylcooxygenases (COX-1 and COX-2), aromatase, nitric oxide production in endotoxin-stimulated macrophages, proliferation of KB or MCF7 cells, induction of quinone reductase I (QRI), accumulation in the sub-G, phase of the cell cycle, and quenching of 2,2-diphenyl-1-picrylhydrazyl (DPPH) free radical. Two metabolites showed activity in these assays; the 3-sulfate exhibited QRI induction, DPPH free radical scavenging, and COX-1 and COX-2 inhibitory activities and the 4'-sulfate inhibited NF kappa B induction, as well as COX-1 and COX-2 activities. Resveratrol and its 3'-sulfate and 4-sulfate inhibit NO production by NO scavenging and down-regulation of iNOS expression in RAW 264.7 cells. Resveratrol sulfates displayed low antiproliferative activity and negligible uptake in MCF7 cells.